Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alnylam Will Seek Early Approval, But Givosiran Likely To Reach Market Later

Executive Summary

Alnylam reported interim Phase III results that it believes support a filing for accelerated approval and a rapid market entry, but a US FDA decision may be delayed by up to six months to allow for a bigger dataset and complete safety assessment in acute hepatic porphyria.

You may also be interested in...



Keeping Track: First RMAT Approval On The Horizon; Big Weeks For Merck, Lilly And Celgene

The latest drug development news and highlights from our US FDA Performance Tracker.

Alnylam Ramps Up Commercial Planning For Givosiran Based On Phase III Data

The company expects to complete a rolling NDA submission for its second RNAi therapeutic in mid-2019, and sees an opportunity to target severe and more moderate patients with acute hepatic porphyria.

Keeping Track: Some Calm Before The Storm

The latest drug development news and highlights from our US FDA Performance Tracker.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC123911

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel